RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A Single-Cell Analysis of the NK-Cell Landscape Reveals That Dietary Restriction Boosts NK-Cell Antitumor Immunity via Eomesodermin.
A Single-Cell Analysis of the NK-Cell Landscape Reveals That Dietary Restriction Boosts NK-Cell Antitumor Immunity via Eomesodermin.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤细胞的异常代谢是肿瘤治疗的潜在靶点。在这方面,饮食限制(DR)或其与抗癌药物的联合应用备受关注,因为它可以抑制肿瘤细胞的生长。除了对肿瘤细胞的作用外,DR还通过调节免疫细胞在限制肿瘤生长方面发挥外在作用。NK细胞是参与肿瘤免疫监视的固有免疫细胞。
然而,DR是否能协助NK细胞控制肿瘤生长仍不确定。在本研究中,我们证明DR有效抑制黑色素瘤细胞向肺部的转移。与此一致的是,在缺乏NK细胞的小鼠中,DR诱导的肿瘤消退微乎其微。单细胞RNA测序分析显示,DR富集了一个 rejuvenated 的CD27+CD11b+ NK细胞亚群。在机制上,DR激活了一个涉及转录因子Eomesodermin(Eomes)的调控网络,该因子对NK细胞发育至关重要。首先,DR通过优化mTORC1信号促进Eomes的表达。Eomes的上调通过拮抗T-bet及下游Zeb2的表达,使功能性CD27+CD11b+ NK细胞亚群恢复活力。
此外,DR通过增加Eomes对染色质的可及性,导致黏附分子和趋化因子表达升高,从而增强NK细胞的功能和趋化性。因此,我们得出结论:DR治疗通过非肿瘤自主机制增强肿瘤免疫,包括促进NK细胞的肿瘤免疫监视和激活。
Abnormal metabolism in tumor cells represents a potential target for tumor therapy. In this regard, dietary restriction (DR) or its combination with anticancer drugs is of interest as it can impede the growth of tumor cells.
In addition to its effects on tumor cells, DR also plays an extrinsic role in restricting tumor growth by regulating immune cells. NK cells are innate immune cells involved in tumor immunosurveillance.
However, it remains uncertain whether DR can assist NK cells in controlling tumor growth. In this study, we demonstrate that DR effectively inhibits metastasis of melanoma cells to the lung. Consistent with this, the regression of tumors induced by DR was minimal in mice lacking NK cells. Single-cell RNA sequencing analysis revealed that DR enriched a rejuvenated subset of CD27+CD11b+ NK cells.
Mechanistically, DR activated a regulatory network involving the transcription factor Eomesodermin (Eomes), which is essential for NK-cell development. First, DR promoted the expression of Eomes by optimizing mTORC1 signaling. The upregulation of Eomes revived the subset of functional CD27+CD11b+ NK cells by counteracting the expression of T-bet and downstream Zeb2.
Moreover, DR enhanced the function and chemotaxis of NK cells by increasing the accessibility of Eomes to chromatin, leading to elevated expression of adhesion molecules and chemokines. Consequently, we conclude that DR therapy enhances tumor immunity through nontumor autonomous mechanisms, including promoting NK-cell tumor immunosurveillance and activation.
MEMBER ACCOUNT
登录成功会直接打开下一页。